BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 2151685)

  • 1. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
    Ortaldo JR; Frey J; Takeshita T; Sugamura K
    Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of CD2 in regulation of CD3- LGL function.
    Mason A; Bernard A; Smyth MJ; Ortaldo JR
    Eur Cytokine Netw; 1991; 2(1):31-7. PubMed ID: 1714784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction.
    Ortaldo JR; Mason AT; O'Shea JJ; Smyth MJ; Falk LA; Kennedy IC; Longo DL; Ruscetti FW
    J Immunol; 1991 Jun; 146(11):3791-8. PubMed ID: 1851793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
    Naume B; Gately M; Espevik T
    J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
    Weil-Hillman G; Voss SD; Fisch P; Schell K; Hank JA; Sosman JA; Sugamura K; Sondel PM
    Cancer Res; 1990 May; 50(9):2683-91. PubMed ID: 1691679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of physiologically secreted IFN-gamma inhibits human T lymphocyte and natural killer cell activation.
    Novelli F; Giovarelli M; Reber-Liske R; Virgallita G; Garotta G; Forni G
    J Immunol; 1991 Aug; 147(4):1445-52. PubMed ID: 1831225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced lymphokine production and lymphokine receptor expression in multiple antibody-stimulated human CD4+ peripheral blood lymphocytes.
    Conlon KC; Ochoa AC; Kopp WC; Ortaldo JR; Urba WJ; Longo DL; Young HA
    J Immunol; 1992 Nov; 149(10):3278-89. PubMed ID: 1358968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of CD3- large granular lymphocyte functions by agonist and antagonists of protein kinase C: effects on NK and lymphokine-activated killer activity and production of IFN-gamma.
    Ortaldo JR; Young HA; Varesio L
    J Immunol; 1989 Jul; 143(1):366-71. PubMed ID: 2543702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
    Kasid A; Bell GI; Director EP
    J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
    Baume DM; Robertson MJ; Levine H; Manley TJ; Schow PW; Ritz J
    Eur J Immunol; 1992 Jan; 22(1):1-6. PubMed ID: 1370410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human retinal pigment epithelial cell interleukin-8 and monocyte chemotactic protein-1 modulation by T-lymphocyte products.
    Elner SG; Elner VM; Bian ZM; Lukacs NW; Kurtz RM; Strieter RM; Kunkel SL
    Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):446-55. PubMed ID: 9040478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of NK-like activity in T cells by IL-2/anti-CD3 is linked to expression of a new antitumour receptor with specificity for acetylated mannose.
    Zollner TM; Zhu HG; Anderer FA
    Anticancer Res; 1993; 13(4):923-30. PubMed ID: 8352560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor.
    Bolhuis RL; Roozemond RC; van de Griend RJ
    J Immunol; 1986 Jun; 136(11):3939-44. PubMed ID: 3084649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity.
    Giovarelli M; Santoni A; Jemma C; Musso T; Giuffrida AM; Cavallo G; Landolfo S; Forni G
    J Immunol; 1988 Oct; 141(8):2831-6. PubMed ID: 3139768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD3/Ti gamma A: a functional gamma-receptor complex expressed on human peripheral lymphocytes.
    Faure F; Jitsukawa S; Triebel F; Hercend T
    J Immunol; 1988 Mar; 140(5):1372-9. PubMed ID: 2964471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Carson WE; Fehniger TA; Caligiuri MA
    Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12.
    van de Wetering D; de Paus RA; van Dissel JT; van de Vosse E
    Int Immunol; 2009 Feb; 21(2):145-53. PubMed ID: 19088061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.